← Back to companies
United States · Surgical robotics · privateThis company was auto-listed from our component database and has not yet had a full editorial review. The facts below come from supplier and product data; treat as unverified until reviewed.
Summary
Symani Surgical System for robotic open soft-tissue microsurgery (microvascular, lymphatic; nerve repair in Europe/APAC). FDA-authorised and CE-marked; ~50 installed systems and ~3,500 procedures worldwide as of Oct 2026.
Key facts
Headquarters
Jacksonville, Florida (founded near Pisa, Italy)
Founded
2015
Role
builder
Category
Medical
Sector
Surgical robotics
Status
private
CEO
Mark Toland
Funding
$125M Series D (Oct 8 2026) led by BioStar Capital
Robots tracked — ranked across 2 companies
Peers — same category & country
ISPeers — same category, other markets
CS
United Kingdom
South KoreaCapital
Funding
$125M Series D (Oct 8 2026) led by BioStar Capital
Status
private
Investors
Primary-source investor lists stay on the interactive company profile. This page does not add investors that are not on the company record.
Figures as recorded by behindrobotics.com from company announcements, filings and market reporting. Verify before citing.